Business Context and Reporting Period
This Form 8-K is filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc., as noted in the request metadata) on November 15, 2021. The filing serves to announce the company's financial results for the quarter ended September 30, 2021. The registrant is an emerging growth company incorporated in Delaware, with its common stock (AVTE) traded on The Nasdaq Global Market.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The actual financial data is contained in the press release furnished as Exhibit 99.1, which is referenced but not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms the announcement of Q3 2021 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in the attached press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are absent from this summary text.
- Confirm the company name is Aerovate Therapeutics, Inc. (AVTE), noting the discrepancy with the "Jade Biosciences" label in the request metadata.
- Review the full press release for any operational updates or clinical trial milestones that may accompany the financial results.
- Check subsequent filings for the incorporation of this data into the company's official 10-Q or 10-K reports.